MedTrace Logo

NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors

NCT05382377 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2022-05-19

No results posted yet for this study

Summary

This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of advanced NKG2DL+ solid tumors.

Conditions

Interventions

BIOLOGICAL

KD-025

Autologous genetically modified anti-NKG2DLs CAR transduced T cells

Sponsors & Collaborators

  • KAEDI

    collaborator OTHER

  • jianming xu

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-17
Primary Completion
2024-05-17
Completion
2026-05-17

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05382377 on ClinicalTrials.gov